PMID- 24288349
OWN - NLM
STAT- MEDLINE
DCOM- 20150511
LR  - 20181202
IS  - 1699-5848 (Electronic)
IS  - 0213-3911 (Linking)
VI  - 29
IP  - 5
DP  - 2014 May
TI  - Immunohistochemical evaluation of EGFR expression in lip squamous cell carcinoma. 
      Correlation with clinicopathological characteristics.
PG  - 641-8
LID - 10.14670/HH-29.10.641 [doi]
AB  - BACKGROUND: The majority of lip cancer is the squamous cell carcinoma (SCC) type 
      that exhibits clinical and biological characteristics intermediate between skin 
      and oral SCC. The aim of this study was to assess the impact of epidermal growth 
      factor receptor (EGFR) expression on prognosis of lip squamous cell carcinoma 
      (LSCC) and to relate it with clinicopathological features. The role of EGFR 
      expression as a possible therapeutic target was also discussed. METHODS: A series 
      of 55 patients with LSCC was analyzed. EGFR expression was determined by 
      standardized immunohistochemistry (pharmDx assay) and evaluated by both manual 
      and automated image analysis (ACIS III). The Kappa statistic test was used to 
      evaluate the concordance of manual and automated scores. EGFR results were 
      correlated with clinicopathologic characteristics. Statistical differences 
      between proportions were determined by the chi-squared test (with 
      linear-by-linear correction where appropriate). The Mann-Whitney and the 
      Kruskal-Wallis test were employed for comparison of continuous variables. 
      RESULTS: Correlation between manual and automated score was obtained in 50/55 
      cases (90.9%). EGFR expression was absent or weak in 14 cases (25.5%); borderline 
      (2+) in 20 cases (36.4%) and positive (3+) in 21 cases (38.2%). Significant 
      relationships were found between EGFR expression and tumour ulceration (p=0.022) 
      and tumour thickness (p=0.002) and width (p=0.021). CONCLUSIONS: Our results 
      revealed EGFR high expression in LSCC and its relationship with bad prognosis 
      criteria (tumour size and ulceration).
FAU - Carballeira, Alexo
AU  - Carballeira A
AD  - Department of Morphological Sciences, Faculty of Medicine and Dentistry - 
      University Clinical Hospital, University of Santiago de Compostela, Spain.
FAU - Ginarte, Manuel
AU  - Ginarte M
AD  - Department of Dermatology, Faculty of Medicine and Dentistry - University 
      Clinical Hospital, University of Santiago de Compostela, Spain. 
      mginartev@aedv.es.
FAU - Diniz-Freitas, Marcio
AU  - Diniz-Freitas M
AD  - Department of Stomatology, Faculty of Medicine and Dentistry - University 
      Clinical Hospital, University of Santiago de Compostela, Spain.
FAU - Fernandez-Campos, Ines
AU  - Fernandez-Campos I
AD  - Department of Pathology, Faculty of Medicine and Dentistry - University Clinical 
      Hospital, University of Santiago de Compostela, Spain.
FAU - Gude, Francisco
AU  - Gude F
AD  - Clinical Epidemiology Unit, Faculty of Medicine and Dentistry - University 
      Clinical Hospital, University of Santiago de Compostela, Spain.
FAU - Fraga, Maximo
AU  - Fraga M
AD  - Department of Pathology, Faculty of Medicine and Dentistry - University Clinical 
      Hospital, University of Santiago de Compostela, Spain.
FAU - Antunez, Jose Ramon
AU  - Antunez JR
AD  - Department of Pathology, Faculty of Medicine and Dentistry - University Clinical 
      Hospital, University of Santiago de Compostela, Spain.
FAU - Garcia-Caballero, Tomas
AU  - Garcia-Caballero T
AD  - Department of Morphological Sciences, Faculty of Medicine and Dentistry - 
      University Clinical Hospital, University of Santiago de Compostela, Spain.
LA  - eng
PT  - Journal Article
DEP - 20131129
PL  - Spain
TA  - Histol Histopathol
JT  - Histology and histopathology
JID - 8609357
RN  - EC 2.7.10.1 (EGFR protein, human)
RN  - EC 2.7.10.1 (ErbB Receptors)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Carcinoma, Squamous Cell/*metabolism/*pathology/secondary
MH  - ErbB Receptors/*metabolism
MH  - Female
MH  - Humans
MH  - Immunohistochemistry/methods
MH  - Lip Neoplasms/*metabolism/*pathology
MH  - Lymphatic Metastasis/pathology
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Recurrence, Local/metabolism/pathology
MH  - Prognosis
MH  - Young Adult
EDAT- 2013/11/30 06:00
MHDA- 2015/05/12 06:00
CRDT- 2013/11/30 06:00
PHST- 2013/11/30 06:00 [entrez]
PHST- 2013/11/30 06:00 [pubmed]
PHST- 2015/05/12 06:00 [medline]
AID - HH-11-428 [pii]
AID - 10.14670/HH-29.10.641 [doi]
PST - ppublish
SO  - Histol Histopathol. 2014 May;29(5):641-8. doi: 10.14670/HH-29.10.641. Epub 2013 
      Nov 29.